s-Figure 2



Supplemental Figure 2. (A) SK-Mel-28 cells treated by UVC (20 J/m2) or UVB (50 mJ/cm2) alone or along with inhibitors of p38 (SB203580, p38i) or CK2 (TBB, CK2i) as indicated. Cell lysates were analyzed by western blot using indicated antibodies. (B) SK-Mel-28 cells treated by UVB (50 mJ/cm2) alone or along with inhibitors of ATM (Ku-55933, 10 μM, ATMi) or ATR (VE-821, 10 μM, ATRi) or DNA-PK (Nu-7441, 10 μM, DNA-PKi) as indicated. Cell lysates were analyzed by western blot using indicated antibodies. (C) ATM+/+ or ATM-/- MEF cells were treated with UVB (50 mJ/cm2). Whole-cell extracts were analyzed with EMSA (NF-κB) and western blot using indicated antibodies. (D) SK-Mel-28 cells, transfected with control (siCtrl) or ATR-targeting (siATR) siRNA, were treated with UVB (50 mJ/cm2). Whole-cell extracts were analyzed with western blots. (E) Supershift analyses of NF-κB complex activated by UVB in SK-Mel-28 cells were performed with indicated antibodies. (F) SK-Mel-28 cells, transfected with control or TAK1-targeting (siTAK1) siRNA, were treated with UVB (50 mJ/cm2). Whole-cell extracts were analyzed with western blots. (G) SK-Mel-28 cells were treated with increasing doses of UVB as shown. After 4 h, western blots were performed as indicated. (H) HEM cells were treated by UVB (50 mJ/cm2). CM and whole-cell extracts (WCE) of treated cells were harvested at the times as shown, and western blotting with the indicated antibodies was performed.